MedTrace Logo

Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation

NCT04342728 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2021-02-16

No results posted yet for this study

Summary

The purpose of this study is to examine the impact of ascorbic acid (vitamin c) and zinc gluconate in reducing duration of symptoms in patients diagnosed with coronavirus disease 2019 (COVID-19). Patients above the age of 18 who present to the Cleveland Clinic outpatient testing and receive a positive test for COVID-19 will be invited to participate.

Conditions

  • COVID
  • Corona Virus Infection

Interventions

DIETARY_SUPPLEMENT

Ascorbic Acid

Readily available marketed open label ascorbic acid

DIETARY_SUPPLEMENT

Zinc Gluconate

Readily available marketed open label zinc gluconate

DIETARY_SUPPLEMENT

Ascorbic Acid and Zinc Gluconate

Readily available marketed open label ascorbic acid and zinc gluconate

OTHER

Standard of Care

Readily available prescribed medications/ supplements- None study supplements

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Milind Desai, M. D. · The Cleveland Clinic

  • Suma Thomas · The Cleveland Clinic

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-08
Primary Completion
2020-12-30
Completion
2021-02-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04342728 on ClinicalTrials.gov